<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480272</url>
  </required_header>
  <id_info>
    <org_study_id>CURE</org_study_id>
    <secondary_id>2006-003843-22</secondary_id>
    <nct_id>NCT00480272</nct_id>
  </id_info>
  <brief_title>Prospective Study on Intensive Early Rheumatoid Arthritis Treatment</brief_title>
  <acronym>CURE</acronym>
  <official_title>A Phase IV Multicenter, Randomized, Double-blind Study. prospeCtive Study on Intensive Early Rheumatoid Arthritis Treatment With adalimUmab: Induction of REmission and Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Early intensive treatment with anti-TNF agent plus methotrexate plus high dose
      prednisone may increase remission rate and may induce stable remission in Rheumatoid
      Arthritis Objective: to evaluate induction of remission using adalimumab, prednisone and
      methotrexate and maintenance of remission after discontinuation of adalimumab and prednisone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment group A 0 - 6 months: Adalimumab 40 mg eow + methotrexate rapidly titrated to 20 mg
      weekly + prednisone 50 mg/d tapered to 6.25 mg 6 - 12 months: Adalimumab 40 mg eow plus
      methotrexate 20 mg weekly group B 0 - 6 months: Adalimumab 40 mg eow + methotrexate rapidly
      titrated to 20 mg weekly + placebo 6 - 12 months: Adalimumab 40 mg eow + methotrexate rapidly
      titrated to 20 mg weekly

      Follow up period - Open Label phase:

      Patients achieving clinical remission will be than treated only with MTX and observed for
      another 12 months period. Patients who do not achieve clinical remission or patients who will
      experience a relapse of the disease will be treated according to standard of care (SOC)
      modalities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">March 1, 2017</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the proportion of subjects who achieve remission at week 52 after treatment, as defined by DAS 28 &lt;/= 2.6</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>subjects who maintain stable remission at 24 months; ACR 20,50,70 at month 4,8,12,24; DAS 28 at month 4,8,12,24; HAQ at week 0,4,8,12,24; radiographic progression at months 12, 24; safety of different treatment regimens</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adalimumab 40 mg subcutaneous injections every other week from baseline to month 12
methotrexate orally weekly at initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.
prednisone orally 50 mg daily, gradually tapered up to 6.25 mg at week 7 and stopped at month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>adalimumab 40 mg subcutaneous injections every other week from baseline to the end of month 12
methotrexate orally oweekly at an initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.
placebo orally, stopped at month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab, plus prednisone</intervention_name>
    <description>adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day</description>
    <arm_group_label>group A</arm_group_label>
    <other_name>humira (adalimumab)</other_name>
    <other_name>deltacortene (prednisone)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab plus placebo</intervention_name>
    <description>adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months</description>
    <arm_group_label>group B</arm_group_label>
    <other_name>humira (adalimumab)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active rheumatoid arthritis diagnosed for at least 6 weeks, but no more than 1 year,
             according to the revised 1987 ACR criteria

          -  Naïve to treatment with MTX

          -  Swollen joint count (SJC) &gt; 8 tender joint count (TJC) &gt; 8

          -  At screening CRP &gt; 1.5 mg/dL (15 mg/L) or ESR ≥ 28 mm/h

          -  ≥ 1 joint erosion or RF positivity or anti-CCP positivity

          -  Age 18-70 years.

        Exclusion Criteria:

          -  Rheumatic autoimmune disease other than RA

          -  Functional class IV

          -  Any surgical procedure within 12 weeks prior to baseline or planned during the study.

          -  Pregnancy or breast feeding.

          -  Evidence of significant concomitant disease

          -  Primary or secondary immunodeficiency

          -  active infection of any kind

          -  History of previously untreated infection with mycobacterium tuberculosis or current
             treatment for same.

          -  History of cancer

          -  Any history or presence of congestive heart failure (CHF) (New York Heart Association
             classification for CHF: Class III or IV).

          -  Any history of myocardial infarction within 5 years.

          -  History of a severe allergic or anaphylactic reaction to a biologic agent or known
             hypersensitivity to any component of adalimumab or methotrexate.

          -  Positive serology for hepatitis B or C indicating active infection.

          -  Hemoglobin &lt; 8.0 g/dL.

          -  Absolute neutrophil count (ANC) &lt; 1.5 x 103/L.

          -  Liver function abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>carlomaurizio montecucco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS S. Matteo Foundation, Pavia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS S. Matteo Hospital</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2007</study_first_submitted>
  <study_first_submitted_qc>May 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2007</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Carlomaurizio Montecucco</investigator_full_name>
    <investigator_title>Director, Academic Division of Rheumatology, IRCCS Policlinico S. Matteo and University of Pavia</investigator_title>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>clinical remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

